Bioptimus

🎉 Excited to share that we've just hit a remarkable $76M funding milestone, with a fresh $41M round led by Cathay Innovation, with participation from prominent investors, including Sofinnova Partners, Bpifrance, Andera Partners, Hitachi Ventures, Boom Capital, Pomifer Capital, Sunrise, and angel entrepreneurs Emmanuel Cassimatis and Thomas Wolf. This comes less than a year after our seed round, demonstrating the tremendous confidence in our vision. Since launching the largest AI foundation model for pathology in July, we've been working tirelessly behind the scenes. Now, we're on the cusp of something truly groundbreaking: a new multi-scale, multi-modal foundation model for biology, set to launch this year. We're not just building technology, we're creating a new paradigm for biological innovation. We’re grateful to our incredible team, investors, and partners who believe in our mission to build the world's first universal AI foundation model for biology. This is just the beginning! 🧬🚀 📰 Read the press release: https://lnkd.in/ecH37kuW #AI #Biotech #Innovation #FundingNews #FoundationModels

📰 FRENCHWEB.FR ranks Bioptimus #3 in the WE INNOVATE 500 Startups for 2025. We're pioneering a multi-scale, multi-modal foundation model for biology. We're not just building technology, we're creating a new paradigm for biological innovation. Access the full list → https://lnkd.in/eHtKvmE8

🧩 Could AI connect the dots across biology and help us understand the science of life? Zelda Mariet, Bioptimus’ Co-Founder & Principal Research Scientist, takes the stage at TEDxParis to explore how foundation models are set to transform medicine. This next-gen AI isn’t just processing data, it’s accelerating breakthroughs at an unprecedented pace, turning decades of research into years, even months. Watch the full talk here → https://lnkd.in/gW6-cwsW

🚀 Announcing Early Access to our latest model 🎉 H-Optimus-1 🎉 : for the Academic & Research community At Bioptimus, we are building a ground-breaking multi-scale, multi-modal #foundationmodel for #biology. Histology has been a crucial first step in that journey—helping us hone our expertise, push the boundaries of our modeling capabilities, and lay the groundwork for what’s to come. After the success of H-Optimus-0, now one of the leading #histology foundation models in the field, we’re taking histology #AI even further with the launch of its successor, H-Optimus-1. Trained on double the number of slides and patients compared to its predecessor, H-Optimus-1 is a 1.1B parameter model that our benchmarking shows is even more powerful and effective than H-0. It enables cutting-edge applications like mutation prediction, survival analysis, and tissue classification/segmentation. Ahead of our commercial launch, we’re opening access to academics and researchers—let’s push the boundaries of computational pathology together.   🔬 Get access through Hugging Face here: https://lnkd.in/eBXRTgXQ This is just the beginning—our multi-scale, multi-modal model for biology is on the horizon 😎 #MachineLearning #ComputationalPathology #OpenScience #Digitaltwin #SimulationofBiology

🧬 Can you envision a future where AI connects the dots across biology, from DNA to patients, microbes to medicine? Bioptimus' Co-Founder & Principal Research Scientist, Zelda Mariet, takes the stage 🎙️ at TEDxParis to explore how foundation models are set to revolutionize medicine. This next-gen AI won't just process data, it will "understand" life science, accelerating discoveries from decades to years or even months. Stay tuned for links to the full talk coming soon.

Our Co-Founder & Principal Research Scientist, Zelda Mariet, joins Heather Couture, PhD on the Impact AI podcast to discuss Bioptimus, biology, and foundation models. Zelda unpacks how foundation models are reshaping biology, shares Bioptimus' groundbreaking work, and explains why it matters. 🎧 Listen now: https://lnkd.in/epTgXhGk

Anthony Morel spotlights Bioptimus among France's hottest AI startups at #AIActionSummit on BFM Business. Bioptimus develops a pioneering AI foundation model that connects biology across all scales—from molecules to cells, tissues, and organisms. 🎧 Listen to the episode: https://lnkd.in/eA5VqVWu

We’re excited to share our latest work in collaboration with Owkin, published as a pre-print on arXiv. Large foundation models have defined a new state-of-the-art in digital pathology. But their inference cost can be prohibitive. By applying distillation techniques to H-optimus-0, our histology foundation model, Owkin and Bioptimus have built H0-mini that: 🤖 Reduces the model size by several orders of magnitude 📊 Achieves comparable performance to large FMs at a significantly reduced inference cost 🔬 Demonstrates excellent robustness to variations in staining and scanning conditions. This development opens new perspectives to design lightweight and robust models for digital pathology, without compromising on performance. 📑 Read the full research at https://lnkd.in/eSpKqyZw

Next month, we're sponsoring the AI Hackathon for Glioblastoma Research, taking place on February 3-4, 2025, at Palais Brongniart, Paris. This unique two-day event, presented by Servier and Owkin, will bring together 100 global experts to tackle one of the deadliest forms of brain cancer. Participants will be able to use histology embeddings generated by the latest and most advanced pathology foundation model developed by Bioptimus. Bioptimus is joining other key sponsors, including Amazon Web Services (AWS), 10x Genomics, and La Place Fintech | DeFi. The initiative is part of the AI Action Summit, funded by the French State via #France2030 #AIsummitParis2025

Sending warm holiday wishes from all of us at Bioptimus! May you and your loved ones have a safe and happy holiday season. ❄️☃️